NT Pharma (01011) has released its interim results for 2026, with revenue surging 97.29% year-on-year to RMB23.665 million. The company recorded a loss attributable to shareholders of RMB18.433 million, an increase of 9.03% compared to the same period last year, translating to a loss per share of RMB0.0224.

The group has established a multi-dimensional and synergistic business framework. Its core therapeutic segment is anchored by the specialised distribution and marketing of the innovative osteoporosis drug teriparatide, complemented by distinctive bone health traditional Chinese medicines and wellness products, forming a solid operational foundation.

Building on this base, the group has strategically expanded into diagnostic services through the acquisition of an AI-powered bone health diagnostic robot. These intelligent devices utilise AI algorithms to deliver efficient and precise screening for bone density and bone health risks, addressing a critical gap in the group's early-stage bone health screening capabilities.